0001628280-26-028852
SEC filingNutex Health reported Q1 2026 financial results with total revenue of $216.5 million, up 2.2% year-over-year, and net income attributable to Nutex Health of $46.8 million, or diluted EPS of $6.52.
Nutex Health delivered strong Q1 2026 results, with total revenue rising 2.2% to $216.5 million, primarily from 1.8% growth in the hospital division to $207.6 million, supported by higher acuity claims and favorable Independent Dispute Resolution (IDR) outcomes where the Company prevails in over 85% of cases and collects over 80% of awards. Same-hospital revenue grew modestly by 0.2%, while total hospital visits increased 3.1% year-over-year to 49,742. Net income attributable to Nutex Health more than doubled to $46.8 million from $21.2 million, driving diluted EPS to $6.52 from $3.33, bolstered by a sharp reduction in stock-based compensation expense to $(3.9) million from $27.6 million. EBITDA rose to $68.3 million, though Adjusted EBITDA dipped to $57.6 million amid higher finance lease payments. Operating cash flow surged to $75.5 million from $51.0 million, reflecting robust cash generation, with cash and equivalents reaching a record $207.3 million and long-term debt declining to $24.3 million. Management highlighted operational progress in patient volumes and inpatient admissions, on track for three to five annual hospital developments, with Board approval for selective self-development starting 2026 to strengthen the pipeline. CFO Jon Bates emphasized the strong balance sheet positioning for growth, including three new openings later this year, while CEO Tom Vo underscored internal process improvements and long-term confidence.